Not recruiting

Study on How REGN9933 and REGN7508 Help Prevent Blood Clots in Adults with a Peripherally Inserted Central Catheter (PICC)

Fast replyInvestigational

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the prevention of venous thromboembolism, which is a condition where blood clots form in the veins. The study involves two investigational treatments, REGN9933 and REGN7508, which are types of monoclonal antibodies. Monoclonal antibodies are special proteins designed to target specific substances in the body. In this case, they target a protein involved in blood clotting called Factor XI. The trial will compare the effects of these treatments to a placebo in patients who have a peripherally inserted central catheter (PICC), a type of long-term intravenous line.

The purpose of the study is to evaluate how well REGN9933 and REGN7508 work in preventing blood clots and to assess their safety. Participants in the study will receive either REGN9933, REGN7508, or a placebo. The treatments are given as a powder mixed into a solution and administered through an intravenous infusion, which means they are delivered directly into the bloodstream. The study will monitor participants for any side effects and measure the concentration of the drugs in the body over time.

Throughout the study, the incidence of blood clots and any bleeding events will be closely observed. The study aims to provide valuable information on the effectiveness and safety of these treatments in preventing blood clots in patients with a PICC. This research could potentially lead to new ways to prevent venous thromboembolism in patients who require long-term intravenous access.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Joining the study
Upon joining the study, eligibility is confirmed based on specific criteria such as having a peripherally inserted central catheter (PICC) expected to remain for at least 14 days, a body weight between 50 kg and 130 kg, and normal blood test results for clotting and platelet count.
Step 2
Randomization and treatment assignment
Participants are randomly assigned to receive either the study medication or a placebo. The study medications are REGN9933 and REGN7508, both administered as a powder for solution for infusion through intravenous use.
Step 3
Treatment administration
The assigned treatment is administered intravenously. The frequency and duration of administration are determined by the study protocol, focusing on preventing blood clots in patients with a PICC.
Step 4
Monitoring and follow-up
Participants are monitored for the incidence of confirmed venous thromboembolism (VTE) and any treatment-emergent adverse events. Regular assessments include checking for PICC-associated thrombosis, major bleeding, and changes in blood clotting times.
Blood samples may be taken to measure the concentration of the study medications and to check for any antibodies that might develop against them.
Step 5
Completion of the study
The study is expected to conclude by June 2026. Participants will have a final assessment to evaluate the overall safety and effectiveness of the treatment they received.

Who can join the trial?

8 criteria

The patient must have a **PICC** (a type of long, thin tube inserted into a vein) that is expected to stay in place for at least 14 days.
The patient should have an **ECOG Performance Status** of 2 or less. This is a scale that measures how well a patient can perform daily activities.
The patient's body weight should be between 50 kg (about 110 pounds) and 130 kg (about 286 pounds) during the screening period.
The patient's **INR** (a blood test that measures how long it takes for blood to clot) and **aPTT** (another blood clotting test) should be at or below the normal range as defined by the local lab during the screening period.
The patient's **platelet count** (a measure of the number of platelets in the blood, which help with clotting) should be at least 100 x 10^9/L during the screening period.
Other criteria defined in the study protocol may also apply.
The study is open to both male and female participants.
The study is not specifically targeting vulnerable populations.

Who cannot join the trial?

6 criteria

Patients who have a history of **venous thromboembolism** (a condition where blood clots form in the veins) cannot participate.
Patients who are not within the specified age range for the study cannot participate.
Patients who are part of a vulnerable population, such as those unable to give consent, cannot participate.
Patients who have any medical condition that the study doctors believe would make it unsafe for them to participate cannot join the study.
Patients who are currently participating in another clinical trial cannot participate in this study.
Patients who have had a **peripherally inserted central catheter (PICC)** (a long, thin tube inserted into a vein in the arm) placed recently cannot participate.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Hospital Universitario 12 De Octubre
Verified
Madrid, Spain
Hospital Universitario De Navarra
Verified
Pamplona, Spain
Spitalul Clinic Judetean De Urgenta Cluj
Responsive
Cluj Napoca, Romania

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

REGN9933
is a monoclonal antibody being studied for its ability to prevent venous thromboembolism (VTE) in patients who have had a peripherally inserted central catheter (PICC) placed. This medication works by targeting a specific factor in the blood that is involved in clot formation, potentially reducing the risk of developing dangerous blood clots.
REGN7508
is another monoclonal antibody included in the study, also aimed at preventing venous thromboembolism (VTE) in patients with a peripherally inserted central catheter (PICC). Similar to REGN9933, this medication targets a factor in the blood that contributes to clotting, helping to prevent the formation of harmful blood clots.

What is already known about the treatment

REGN9933
This medication is administered as an injection and is currently being studied in clinical trials for its effectiveness in preventing venous thromboembolism, particularly in patients with a peripherally inserted central catheter. It is a monoclonal antibody targeting Factor XI, which plays a role in blood clot formation. By inhibiting Factor XI, REGN9933 aims to reduce the risk of clotting without significantly affecting normal blood coagulation. It falls under the pharmacological classification of anticoagulants.
REGN7508
This medication is also administered via injection and is under investigation in clinical trials for its potential to prevent venous thromboembolism in patients with a peripherally inserted central catheter. Like REGN9933, it is a monoclonal antibody that targets Factor XI, a key component in the blood clotting process. By blocking Factor XI, REGN7508 seeks to lower the risk of clot formation while maintaining normal blood clotting functions. It is classified as an anticoagulant.

Investigated diseases

Venous Thromboembolism – This condition involves the formation of blood clots in the veins, which can lead to complications if the clots travel to other parts of the body. It typically begins with a clot forming in a deep vein, often in the legs, known as deep vein thrombosis (DVT). If a part of this clot breaks off, it can travel to the lungs, causing a pulmonary embolism (PE), which can obstruct blood flow. Symptoms may include swelling, pain, and redness in the affected area, as well as shortness of breath and chest pain if a PE occurs. The condition can develop after certain medical procedures, such as the placement of a peripherally inserted central catheter (PICC). Regular monitoring and preventive measures are important to manage the risk of clot formation.